Clinical management of multiple sclerosis and neuromyelitis optica with therapeutic monoclonal antibodies: Approved therapies and emerging candidates

Divyanshu Dubey, Bernd C. Kieseier, Hans Peter Hartung, Bernhard Hemmer, William A. Miller-Little, Olaf Stuve

Research output: Contribution to journalReview article

13 Citations (Scopus)

Abstract

Therapeutic monoclonal antibodies (mAbs) are a relatively novel class of drugs that has substantially advanced immunotherapy for patients with multiple sclerosis. The advantage of these agents is that they bind specifically and exclusively to predetermined proteins or cells. Natalizumab was the first mAb in neurology to obtain approval. It is also considered one of the most potent options for annualized relapse rate reduction among available therapeutic options. Alemtuzumab is currently also approved in several countries. Several mAbs have been tested in clinical studies in multiple sclerosis. Here, we review the history of drug development of therapeutic mAbs and their classification. Furthermore, we outline the putative mechanisms of action, clinical evidence and safety of approved mAbs and those in different stages of clinical development in multiple sclerosis and neuromyelitis optica.

Original languageEnglish (US)
Pages (from-to)93-108
Number of pages16
JournalExpert Review of Clinical Immunology
Volume11
Issue number1
DOIs
StatePublished - Jan 1 2014
Externally publishedYes

Fingerprint

Neuromyelitis Optica
Multiple Sclerosis
Monoclonal Antibodies
Therapeutics
Neurology
Pharmaceutical Preparations
Immunotherapy
History
Safety
Recurrence
Proteins

Keywords

  • monoclonal antibodies
  • MS
  • multiple sclerosis
  • pharmacology
  • therapies

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Clinical management of multiple sclerosis and neuromyelitis optica with therapeutic monoclonal antibodies : Approved therapies and emerging candidates. / Dubey, Divyanshu; Kieseier, Bernd C.; Hartung, Hans Peter; Hemmer, Bernhard; Miller-Little, William A.; Stuve, Olaf.

In: Expert Review of Clinical Immunology, Vol. 11, No. 1, 01.01.2014, p. 93-108.

Research output: Contribution to journalReview article

Dubey, Divyanshu ; Kieseier, Bernd C. ; Hartung, Hans Peter ; Hemmer, Bernhard ; Miller-Little, William A. ; Stuve, Olaf. / Clinical management of multiple sclerosis and neuromyelitis optica with therapeutic monoclonal antibodies : Approved therapies and emerging candidates. In: Expert Review of Clinical Immunology. 2014 ; Vol. 11, No. 1. pp. 93-108.
@article{3021e70af2f1465da2357c14a86c0038,
title = "Clinical management of multiple sclerosis and neuromyelitis optica with therapeutic monoclonal antibodies: Approved therapies and emerging candidates",
abstract = "Therapeutic monoclonal antibodies (mAbs) are a relatively novel class of drugs that has substantially advanced immunotherapy for patients with multiple sclerosis. The advantage of these agents is that they bind specifically and exclusively to predetermined proteins or cells. Natalizumab was the first mAb in neurology to obtain approval. It is also considered one of the most potent options for annualized relapse rate reduction among available therapeutic options. Alemtuzumab is currently also approved in several countries. Several mAbs have been tested in clinical studies in multiple sclerosis. Here, we review the history of drug development of therapeutic mAbs and their classification. Furthermore, we outline the putative mechanisms of action, clinical evidence and safety of approved mAbs and those in different stages of clinical development in multiple sclerosis and neuromyelitis optica.",
keywords = "monoclonal antibodies, MS, multiple sclerosis, pharmacology, therapies",
author = "Divyanshu Dubey and Kieseier, {Bernd C.} and Hartung, {Hans Peter} and Bernhard Hemmer and Miller-Little, {William A.} and Olaf Stuve",
year = "2014",
month = "1",
day = "1",
doi = "10.1586/1744666X.2015.992881",
language = "English (US)",
volume = "11",
pages = "93--108",
journal = "Expert Review of Clinical Immunology",
issn = "1744-666X",
publisher = "Expert Reviews Ltd.",
number = "1",

}

TY - JOUR

T1 - Clinical management of multiple sclerosis and neuromyelitis optica with therapeutic monoclonal antibodies

T2 - Approved therapies and emerging candidates

AU - Dubey, Divyanshu

AU - Kieseier, Bernd C.

AU - Hartung, Hans Peter

AU - Hemmer, Bernhard

AU - Miller-Little, William A.

AU - Stuve, Olaf

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Therapeutic monoclonal antibodies (mAbs) are a relatively novel class of drugs that has substantially advanced immunotherapy for patients with multiple sclerosis. The advantage of these agents is that they bind specifically and exclusively to predetermined proteins or cells. Natalizumab was the first mAb in neurology to obtain approval. It is also considered one of the most potent options for annualized relapse rate reduction among available therapeutic options. Alemtuzumab is currently also approved in several countries. Several mAbs have been tested in clinical studies in multiple sclerosis. Here, we review the history of drug development of therapeutic mAbs and their classification. Furthermore, we outline the putative mechanisms of action, clinical evidence and safety of approved mAbs and those in different stages of clinical development in multiple sclerosis and neuromyelitis optica.

AB - Therapeutic monoclonal antibodies (mAbs) are a relatively novel class of drugs that has substantially advanced immunotherapy for patients with multiple sclerosis. The advantage of these agents is that they bind specifically and exclusively to predetermined proteins or cells. Natalizumab was the first mAb in neurology to obtain approval. It is also considered one of the most potent options for annualized relapse rate reduction among available therapeutic options. Alemtuzumab is currently also approved in several countries. Several mAbs have been tested in clinical studies in multiple sclerosis. Here, we review the history of drug development of therapeutic mAbs and their classification. Furthermore, we outline the putative mechanisms of action, clinical evidence and safety of approved mAbs and those in different stages of clinical development in multiple sclerosis and neuromyelitis optica.

KW - monoclonal antibodies

KW - MS

KW - multiple sclerosis

KW - pharmacology

KW - therapies

UR - http://www.scopus.com/inward/record.url?scp=84919794431&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84919794431&partnerID=8YFLogxK

U2 - 10.1586/1744666X.2015.992881

DO - 10.1586/1744666X.2015.992881

M3 - Review article

C2 - 25495182

AN - SCOPUS:84919794431

VL - 11

SP - 93

EP - 108

JO - Expert Review of Clinical Immunology

JF - Expert Review of Clinical Immunology

SN - 1744-666X

IS - 1

ER -